Osimertinib inhibits brain metastases and improves long-term survival in a patient with advanced squamous cell lung cancer: a case report and literatures review

Frontiers in Oncology

Oncology

Linke Yang¹  Zhiqin Zhang²  Jiamao Lin³  Yang Li⁴ 

[1] Department of Pathology, Shandong Cancer Hospital and Institute, Shandong First Medical University, Academy of Medical Sciences, Jinan, China;Department of Radiation Oncology, Shandong Cancer Hospital Affiliated to Shandong First Medical University, Jinan, China;Department of Radiation Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University, Academy of Medical Sciences, Jinan, China;Department of Traditional Chinese and Western Medicine, Shandong Cancer Hospital and Institute, Shandong First Medical University, Academy of Medical Sciences, Jinan, China;Shandong Provincial Key Laboratory of Radiation Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University, Academy of Medical Sciences, Jinan, China;

关键词: non-small cell lung carcinoma;    squamous cell carcinoma;    EGFR mutation;    targeted therapy;    cancer;   

DOI  :  10.3389/fonc.2023.1188772

 received in 2023-03-17, accepted in 2023-08-07,  发布年份 2023

来源: Frontiers

【 摘 要 】

BackgroundSquamous cell carcinoma (SCC) is one of the most common subtypes of non-small cell lung cancer, but its treatment options remain limited. Epidermal growth factor receptor (EGFR)–tyrosine kinase inhibitors (TKIs) have limited efficacy in the treatment of lung SCC. Here, we report an SCC patient who developed EGFR-T790M mutation and showed gefitinib resistance achieved an extremely long survival by taking Osimertinib alternatively.Case summaryA patient, 66-year-old non-smoking and drinking male with advanced SCC who was deemed inoperable at the time of diagnosis. The first genetic testing showed deletion mutation of exon 19 of EGFR. The patient was then treated with gefitinib with no significant efficacy. EGFR-T790M mutation was found in the second genetic test. The treatment regimen was changed to radiotherapy with Osimertinib, and the patient’s primary lesion and the brain metastases were well controlled.ConclusionThis typical case highlights the important role of Osimertinib in patients with SCC carrying EGFR mutations.

【 授权许可】

Unknown   
Copyright © 2023 Zhang, Lin, Yang and Li